BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $293

Benzinga · 17h ago
BMO Capital analyst David Lebowitz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the price target from $292 to $293.